AVACTA GROUP PLC |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 49.17 GBX | +0.75% |
|
+10.24% | -57.80% |
| 22/04 | First Tin updates Tellerhauser estimates | AN |
| 10/04 | Transcript : Avacta Group Plc - Special Call |
| Sales 2023 * | 23.08M 28.93M 2.41B | Sales 2024 * | 26.12M 32.74M 2.73B | Capitalization | 173M 217M 18.12B |
|---|---|---|---|---|---|
| Net income 2023 * | -23M -28.83M -2.4B | Net income 2024 * | -32M -40.11M -3.34B | EV / Sales 2023 * | 6.81 x |
| Net cash position 2023 * | 16.2M 20.3M 1.69B | Net cash position 2024 * | 7.3M 9.15M 763M | EV / Sales 2024 * | 6.36 x |
| P/E ratio 2023 * |
-5.88
x | P/E ratio 2024 * |
-4.32
x | Employees | 120 |
| Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 70.66% |
More Fundamentals
* Assessed data
More news
Latest transcript on Avacta Group Plc
More press releases
| 1 day | +0.75% | ||
| 1 week | +10.24% | ||
| Current month | -1.17% | ||
| 1 month | -2.16% | ||
| 3 months | -50.83% | ||
| 6 months | -62.75% | ||
| Current year | -57.80% |
1 week
43.00
50.25
1 month
43.0057.90
Current year
43.00119.85
1 year
43.00166.98
3 years
38.00283.96
5 years
13.00291.80
10 years
13.00291.80
| Managers | Title | Age | Since |
|---|---|---|---|
Alastair Smith
FOU | Founder | - | 01/04/01 |
Tony Gardiner
DFI | Director of Finance/CFO | 53 | 04/16/04 |
Matt Johnson
CTO | Chief Tech/Sci/R&D Officer | - | 16/13/16 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Trevor Nicholls
BRD | Director/Board Member | 67 | 02/13/02 |
Alastair Smith
FOU | Founder | - | 01/04/01 |
Tony Gardiner
DFI | Director of Finance/CFO | 53 | 04/16/04 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 29/24/29 | 49.17 | +0.75% | 2 005 345 |
| 26/24/26 | 48.8 | +8.44% | 5,616,464 |
| 25/24/25 | 45 | -0.66% | 2,875,504 |
| 24/24/24 | 45.3 | +1.80% | 4,277,570 |
| 23/24/23 | 44.5 | -0.22% | 4,370,117 |
Delayed Quote London S.E., April 29, 2024 at 06:17 pm IST
More quotes
Avacta Group plc is a United Kingdom-based life sciences company focused on improving healthcare outcomes through targeted cancer treatments and diagnostics. The Company has two segments: Therapeutics and Diagnostics. The Therapeutics segment is a clinical stage oncology biotech division harnessing therapeutic platforms to develop novel, highly targeted cancer drugs. The Diagnostics segment is focused on supporting healthcare professionals and broadening access to diagnostics. It has two platforms: preICISION and Affimer. The Company's preICISION platform is a highly specific substrate for fibroblast activation protein (FAP) which is upregulated in most solid tumors compared with healthy tissues. The preICISION platform harnesses this tumor specific protease to activate preICISION peptide drug conjugates and preICISION antibody/Affimer drug conjugates in the tumor microenvironment. Its lead preICISION program AVA6000, a peptide drug conjugate form of doxorubicin, is in Phase 1 studies.
Calendar
30/04/2024
- Q4 2023 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
0.488
GBP
Average target price
0.9233
GBP
Spread / Average Target
+89.21%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -57.80% | 216M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +0.55% | 22.15B | |
| -17.37% | 21.02B | |
| -8.96% | 18.15B | |
| -41.01% | 16.73B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- AVCT Stock
